Information Provided By: 
Fly News Breaks for February 12, 2016
PTLA
Feb 12, 2016 | 07:06 EDT
Citi analyst Yigal Nochomovitz says the likely FDA approval of Portola Pharmaceuticals' antidote for blood thinning drugs andexanet alfa in August brings minimal downside risk into the Phase 3 readout for betrixaban in late Q1. The novel blood thinner is risky, but investors are not assuming success with Portola shares around $30, Nochomovitz tells investors in a research note. If the APEX trial is successful, the analyst sees value of $40 per share. He keeps a Buy rating on Portola Pharmaceuticals with a $40 price target.
News For PTLA From the Last 2 Days
There are no results for your query PTLA
